UNASSIGNED: 10020 Background: Local recurrence after complete surgical resection represents the leading cause of death in retroperitoneal soft tissue @entity242 (RSTS). @entity1161 ( @entity1161 ) is widely used in STS of the extremities, but is problematic post-operatively in RSTS. High dose long-infusion @entity1260 (HLI) as a single agent is known to be active in advanced @entity242 and may be a radiosensitizer. We then decided to study the feasibility, safety and activity of the combination of HLI and @entity1161 as preoperative treatment for resectable localized RSTS. METHODS: @entity1 received 3 cycles of HLI (14 g/m(2)), given as a continuous infusion in 14 days. @entity1161 was started in combination with the onset of the 2nd cycle and administered up to a total dose of 50.4 Gy in 28 fractions. Response rate was evaluated by RECIST at the time of surgery. Surgery was scheduled 4-6 weeks after the end of @entity1161 . An intra-operative boost (IORT) was allowed when clinically indicated. 3-yr local relapse-free survival (LRFS), distant recurrence-free survival (DRFS) and @entity1349 ( @entity1349 ) were calculated from the time of surgery. RESULTS: Between December 2003 and December 2010, 86 @entity1 were recruited. 2 @entity1 were ineligible following central pathological review. The overall preoperative treatment plan was completed in 61 @entity1 . CT was completed in 65 @entity1 , while @entity1161 in 74 @entity1 . A partial response was obtained in 7 @entity1 , while stable disease was observed in 62. One @entity1 had systemic progression during preoperative therapy and was not operated. 79 @entity1 underwent surgery (macroscopically complete in 70). IORT was delivered in 15 @entity1 (median dose 12,0 Gy). At a median follow-up of 1.8 years (IQ range = 0.6-3.7), 3-yr LRFS, DRFS and @entity1349 were 66%, 79% and 80%, respectively. CONCLUSIONS: The combination of preoperative HDI and @entity1161 is feasible and relatively safe, although 1/3 of the @entity1 could not complete it. Pts had to suspend HDI more often than @entity1161 . A formal phase III study should preferably address the role of @entity1161 alone.

Preoperative chemoradiation therapy for localized retroperitoneal soft tissue XXXX (RSTS): A phase II study from the Italian @entity242 Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['RT', 'Radiation therapy'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['Ifosfamide'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity242 :: (MESH:D012509,Disease) :: ['sarcoma']
